Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 May 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Anti-rotavirus protein reduces stool output in infants with diarrhea

The latest issue of Gastroenterology finds that anti-rotavirus protein reduces stool output in infants with diarrhea.

News image

Rotavirus infection is a leading cause of morbidity and mortality in children younger than 5 years of age.

Current treatment options are limited.

Dr Shafiqul Sarker and colleagues from India assessed the efficacy of a llama-derived, heavy-chain antibody fragment called anti-rotavirus protein (ARP1), in modifying the severity and duration of diarrhea in male infants with rotavirus infection.

The research team performed a double-blind, placebo-controlled trial of 176 male infants with severe rotavirus-associated diarrhea at Dhaka Hospital, Bangladesh.

The infants were randomly assigned to groups given oral ARP1 or placebo for a maximum of 5 days.

Total cumulative stool output was 305.47 g/kg body weight among those given placebo
Gastroenterology

The primary outcomes were severity (stool output) and duration of diarrhea and fecal excretion of rotavirus.

The team's secondary outcomes were intake of oral rehydration salt solution, severity of vomiting, and serum levels of rotavirus-specific IgA.

In infants with only rotavirus infection, total cumulative stool output was 305.47 g/kg body weight among those given placebo, and 237.03 g/kg body weight among those given ARP1.

The research team found a significant reduction in rate of stool output (g/kg/d) in the ARP1 group compared with the placebo group.

The team noted that ARP1 had no significant effect in infants with concomitant infections or on any other measured outcomes.

No adverse events could be linked to ARP1.

Dr Sarker's team concludes, "In a placebo-controlled trial, ARP1 reduced stool output in male infants with severe rotavirus-associated diarrhea."

Gastroenterol 2013: 145(4): 740-748.e8
27 September 2013

Go to top of page Email this page Email this page to a colleague

 25 May 2016 
Preventing NSAID-associated GI toxicity
 25 May 2016 
Recurrence of Barrett’s after successful endoscopic therapy
 25 May 2016 
PPIs and NSAID-induced small bowel injury
 24 May 2016 
Fecal inflammatory markers in Crohn's
 24 May 2016 
Depression and IBD recurrence
 24 May 2016 
New therapies for NASH
 23 May 2016 
Risk factors for peptic ulcer bleeding outcomes
 23 May 2016 
Liver transplantation for hepatocellular carcinoma
 23 May 2016 
Cancer after colectomy in IBD
 20 May 2016 
Biomarker for colorectal cancer diagnosis
 20 May 2016 
Prognostic score for hepatic venous outflow obstruction
 20 May 2016 
Treatment for uncomplicated acute diverticulitis
 19 May 2016 
Probiotics and H. pylori eradication
 19 May 2016 
Impaired skeletal health in atrophic gastritis
 19 May 2016 
Predicting outcome in ulcerative colitis
 18 May 2016 
Erectile dysfunction in IBD
 18 May 2016 
Acute GERD and esophageal histologic changes
 18 May 2016 
Surgical fundoplication for GERD 
 17 May 2016 
Mucosal dysbiosis in Crohn's disease
 17 May 2016 
Vitamin D level and clinical status in IBD 
 17 May 2016 
Inpatient costs for IBD and acute pancreatitis
 16 May 2016 
Outcomes of postcolonoscopy colorectal cancers
 16 May 2016 
C. difficile in ulcerative colitis patients
 16 May 2016 
Therapy for Crohn's in a Medicaid population
 13 May 2016 
Parkinson's disease and IBD
 13 May 2016 
Non-traditional heart disease risk factors in NAFLD
 13 May 2016 
Inactivated oral cholera vaccine
 12 May 2016 
Gestational diabetes mellitus and NAFLD
 12 May 2016 
Impact of Crohn's in the USA
 12 May 2016 
Ozanimod induction and ulcerative colitis
 11 May 2016 
Anti-TNF discontinuation in IBD
 11 May 2016 
Age and disease presentation with Crohn's disease
 11 May 2016 
Prognosis after colorectal cancer resection
 10 May 2016 
Gluten-free diet in patients with IBS-diarrhea
 10 May 2016 
Noninvasive test for IBD
 10 May 2016 
Digital health for gastroenterology
 09 May 2016 
Diarrheal infections in adults
 09 May 2016 
Quality improvement initiative and readmission for cirrhosis
 09 May 2016 
Coffee or tea and the risk of Barrett's
 06 May 2016 
Recurrent pancreatitis after acute pancreatitis
 06 May 2016 
Risk factors in peptic ulcer bleeding
 06 May 2016 
Managing acute lower GI bleeding
 05 May 2016 
Chemoradiotherapy vs chemotherapy for pancreatic cancer
 05 May 2016 
Reductions in quality of screening colonoscopies
 05 May 2016 
Genetics in early-early-onset IBD
 04 May 2016 
Anti-TNF therapy for IBD
 04 May 2016 
Bismuth and H. pylori eradication
 04 May 2016 
Chromoendoscopy vs colonoscopy for dysplasia in colitis
 03 May 2016 
Vedolizumab for IBD
 03 May 2016 
PPIs and gut microbiota
 03 May 2016 
Surgery vs medical therapy for GERD
 02 May 2016 
Mycophenolate mofetil as first-line treatment of autoimmune hepatitis
 02 May 2016 
Genetic variant that increase NAFLD risk
 02 May 2016 
Resection of colorectal polyps
 29 April 2016 
Simvastatins and survival in cirrhosis
 29 April 2016 
HCV infection in Baby Boomers with Medicare
 29 April 2016 
Crohn's disease associated genes
 28 April 2016 
Diarrheal diseases in children
 28 April 2016 
Birth outcomes in women with IBD receiving assisted reproduction
 28 April 2016 
Racial disparities in survival from colon cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us